PolyMedix Inc. (PYMX) announced that the United States Adopted Names or USAN Council, in consultation with the World Health Organization or WHO International Nonproprietary Names Expert Committee, has approved the use of the nonproprietary generic name "brilacidin" (pronounced bri-la-ci-din) for PMX-30063, a first-in-class defensin mimetic antibiotic.
PolyMedix said it recently announced positive results from a Phase 2 clinical study with brilacidin as an intravenous treatment in patients with acute bacterial skin and skin structure Staph aureus infections.
The company said that the USAN Council has also approved the use of the nonproprietary generic name "delparantag" (pronounced del-par-an-tag) for PMX-60056, PolyMedix's first-in-class anticoagulant reversing agent.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.